摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[2-氨基-2-(3-甲氧基-苯基)-乙基]-氨基甲酸叔丁酯 | 912762-85-7

中文名称
[2-氨基-2-(3-甲氧基-苯基)-乙基]-氨基甲酸叔丁酯
中文别名
[2-氨基-2-(3-甲氧基苯基)乙基]氨基甲酸叔丁基酯
英文名称
tert-butyl [2-amino-2-(3-methoxyphenyl)ethyl]carbamate
英文别名
[2-Amino-2-(3-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester;tert-butyl N-[2-amino-2-(3-methoxyphenyl)ethyl]carbamate
[2-氨基-2-(3-甲氧基-苯基)-乙基]-氨基甲酸叔丁酯化学式
CAS
912762-85-7
化学式
C14H22N2O3
mdl
——
分子量
266.34
InChiKey
PCQAWAIMUNCTQZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    412.6±45.0 °C(Predicted)
  • 密度:
    1.084±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    73.6
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2924299090

SDS

SDS:a44763a9d3624951c4f38dcf47910000
查看

反应信息

点击查看最新优质反应信息

文献信息

  • ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS
    申请人:Incyte Corporation
    公开号:US20130096144A1
    公开(公告)日:2013-04-18
    The present invention provides isoindolinone and pyrrolopyridinone derivatives, as well as their compositions and methods of use, that inhibit the activity of the serine/threonine kinase, Akt, and are useful in the treatment of diseases related to the activity of Akt including, for example, cancer and other diseases.
    本发明提供了异吲哚酮和吡咯吡啶酮衍生物,以及它们的组合物和使用方法,这些衍生物抑制丝氨酸/苏氨酸激酶Akt的活性,对于治疗与Akt活性相关的疾病,例如癌症和其他疾病,具有益处。
  • COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    申请人:Industrial Technology Research Institute
    公开号:US20190194137A1
    公开(公告)日:2019-06-27
    A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is —C(═Z)—, wherein Z is N—CN, NH, NR 4 , NCOR 4 , NCONR 4 R 5 , NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, —NH 2 , —CN, —OH, —O-alkyl, —O-aryl, —COOH, —COOR 4 , —CONHR 4 , —CONHCH 2 -aryl, —CONR 4 CH 2 -aryl, —NHCOR 4 , halogen, halogened alkyl, -alkyl-OR 4 , -alkyl-ONO 2 , alkyl-ONO 2 , —OCOOR 4 , —O(C═O)-aryl, —CHR 4 OH, —CH 2 OH, —CH 2 O(C═O)-aryl, —CH 2 O(C═O)—R 4 , —CHR 4 O(C═O)-aryl, —CHR 4 O(C═O)—R 4 , unsaturated carboxylic ester, substituted alkynyl, —NHSO 2 R 4 , —SO 2 R 4 , —SO 2 NHR 4 , or —SO 2 NR 4 R 5 , or Y and J bond together to form a carbocylic or aromatic ring, wherein R 4 and R 5 are independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl, -alkyl-NR 6 R 7 , —S(O) 0-2 -(alkyl-NR 6 R 7 ). R 1 , R 2 and R 3 are H, C1-C6 alkyl, cycloalkyl, aryl, alkylaryl, alkylheteroaryl, alkylheterocycle, wherein any one thereof is optionally substituted with one or more of OH, NO 2 , or NR 8 R 9 .
    提供公式(I)的化合物或其药用盐。在公式(I)中,Ar是吲唑,5-异喹啉,6-异喹啉或它们的N-氧化物。X为—C(═Z)—,其中Z为N—CN,NH,NR4,NCOR4,NCONR4R5,NCO-芳基,S或O。Y和J独立地为H,烷基,芳基,氨基烷基,—NH2,—CN,—OH,—O-烷基,—O-芳基,—COOH,—COOR4,—CONHR4,—CONHCH2-芳基,—CONR4CH2-芳基,—NHCOR4,卤素,卤代烷基,-烷基-OR4,-烷基-ONO2,烷基-ONO2,—OCOOR4,—O(C═O)-芳基,—CHR4OH,—CH2OH,—CH2O(C═O)-芳基,—CH2O(C═O)—R4,—CHR4O(C═O)-芳基,—CHR4O(C═O)—R4,不饱和羧酸酯,取代炔烃基,—NHSO2R4,—SO2R4,—SO2NHR4或—SO2NR4R5,或Y和J结合在一起形成环,其中R4和R5独立地为H,取代的C1-C6烷基,取代的芳基,环烷基,烷基芳基,-烷基-NR6R7,—S(O)0-2-(烷基-NR6R7)。R1,R2和R3为H,C1-C6烷基,环烷基,芳基,烷基芳基,烷基杂芳基,烷基杂环,其中任意一个可以选择地取代一个或多个OH,NO2或NR8R9。
  • [EN] BENZOUREA RING DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] DÉRIVÉ DE CYCLO-BENZO-URÉE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 苯并脲环衍生物及其制备方法和应用
    申请人:MEDSHINE DISCOVERY INC
    公开号:WO2022100614A1
    公开(公告)日:2022-05-19
    式(I)所示的苯并脲环衍生物或其药学上可接受的盐以及其制备方法和应用。
  • ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS
    申请人:Industrial Technology Research Institute
    公开号:EP3505513A1
    公开(公告)日:2019-07-03
    A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is -C(=Z)-, wherein Z is N-CN, NH, NR4, NCOR4, NCONR4R5, NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, -NH2, -CN, -OH, -O-alkyl, -O-aryl, -COOH, -COOR4, -CONHR4, -CONHCH2-aryl, -CONR4CH2-aryl,-NHCOR4, halogen, halogened alkyl, -alkyl-OR4, -O-alkyl-OR4, -alkyl-ONO2, O-alkyl-ONO2, -OCOOR4, -O(C=O)-aryl, -CHR4OH, -CH2OH, -CH2O(C=O)-aryl,-CH2O(C=O)-R4, -CHR4O(C=O)-aryl, -CHR4O(C=O)-R4, unsaturated carboxylic ester, substituted alkynyl, -NHSO2R4, -SR4, -SO2R4, -SO2NHR4, or -SO2NR4R5, or Y and J bond together to form a carbocylic or aromatic ring, wherein R4 and R5 are independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl,-alkyl-NR6R7, -alkyl-OR6, -alkyl-ONO2, -S(O)0-2-(alkyl-NR6R7). R1, R2 and R3 are H, C1-C6 alkyl, cycloalkyl, aryl, alkylaryl, alkylheteroaryl, alkylheterocycle, wherein any one thereof is optionally substituted with one or more of OH, NO2, or NR8R9.
    提供了一种式(I)化合物或其药学上可接受的盐。在式 (I) 中,Ar 是吲唑、5-异喹啉、6-异喹啉或它们的 N-氧化物。X 是-C(=Z)-,其中 Z 是 N-CN、NH、NR4、NCOR4、NCONR4R5、NCO-芳基、S 或 O。Y 和 J 独立地为 H、烷基、芳基、氨基烷基、-NH2、-CN、-OH、-O-烷基、-O-芳基、-COOH、-COOR4、-CONHR4、-CONHCH2-芳基、-CONR4CH2-芳基、-NHCOR4、卤素、卤代烷基、-alkyl-OR4、-O-alkyl-OR4、-alkyl-ONO2、O-alkyl-ONO2、-OCOOR4、-O(C=O)-芳基、-CHR4OH、-CH2OH、-CH2O(C=O)-芳基、-CH2O(C=O)-R4、-CHR4O(C=O)-芳基、-CHR4O(C=O)-R4、不饱和羧酸酯、取代的炔基、-NHSO2R4、-SR4、-SO2R4、-SO2NHR4 或 -SO2NR4R5,或 Y 和 J 键合形成碳环或芳环,其中 R4 和 R5 独立地为 H、取代的 C1-C6 烷基、取代的芳基、环烷基、烷芳基、-烷基-NR6R7、-烷基-OR6、-烷基-ONO2、-S(O)0-2-(烷基-NR6R7)。R1、R2 和 R3 为 H、C1-C6 烷基、环烷基、芳基、烷芳基、烷基杂芳基、烷基杂环基,其中任意一个任选被 OH、NO2 或 NR8R9 中的一个或多个取代。
  • BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR
    申请人:Medshine Discovery Inc.
    公开号:EP3782987A1
    公开(公告)日:2021-02-24
    The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.
    本发明涉及一种用作 RHO 激酶抑制剂的苯并吡唑化合物、制备 RHO 激酶抑制药物的药物组合物及其用途,更具体地说,涉及所述式(I-1)化合物、其药学上可接受的盐和异构体。
查看更多